|1.||Hunter, Christine: 1 article (12/2010)|
|2.||Weiss, Harvey R: 1 article (12/2010)|
|3.||Liu, Xia: 1 article (12/2010)|
|4.||Chi, Oak Z: 1 article (12/2010)|
|5.||Dewey, William L: 1 article (07/2007)|
|6.||Ritter, Joseph K: 1 article (07/2007)|
|7.||Kessler, Fay K: 1 article (07/2007)|
|8.||Smith, Forrest L: 1 article (07/2007)|
|9.||Gabra, Bichoy H: 1 article (07/2007)|
|10.||Steyerberg, Ewout W: 1 article (02/2006)|
03/28/1994 - "Significant protection against mortality due to repetitive ischemia was offered by both CGS-19755 and combination CGS-19755-hypothermia treatments. "
06/01/1996 - "CGS-19755 pretreatment improved postischemic hypoperfusion and PCr/Pi recovery in the 10-min forebrain ischemia model in gerbils. "
01/01/1988 - "The postischemic efficacy of CGS 19755 appears to be due to its ability to block the neurotoxic effects of transient ischemia."
11/09/1998 - "Infarct volumes measured in animals pretreated with CGS 19755 after 24 h of ischemia were significantly smaller than those quantified in ischemic controls. "
07/01/1993 - "CGS-19755 significantly prolonged the P50 (t test, P = .003) when given 5 minutes after ischemia, but not if delayed by 30 or 60 minutes (P50: control, 24.1; 5 minutes, 31.4; 30 minutes, 30.1; 60 minutes, 26.6). "
02/01/2000 - "Selfotel was not an effective treatment for acute ischemic stroke. "
01/01/2004 - "Unfortunately, the trial, already underway, had to be prematurely aborted, since concurrent stroke studies with enrollment of nonintubated patients on low-dose selfotel revealed an increased number of deaths and other adverse events. "
02/01/2000 - "Two pivotal phase 3 ischemic stroke trials tested the hypothesis, by double-blind, randomized, placebo-controlled parallel design, that a single intravenous 1.5 mg/kg dose of Selfotel, administered within 6 hours of stroke onset, would improve functional outcome at 90 days, defined as the proportion of patients achieving a Barthel Index score of >/=60. "
01/04/1997 - "Termination of Acute Stroke Studies Involving Selfotel Treatment. "
04/01/1995 - "The objectives of this multicenter (7 centers), randomized, double-blind, placebo-controlled, ascending-dose phase IIa study were to evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke. "
05/19/1995 - "There was no evidence of neuronal protection in the animals that had received either CGS-19755 alone or a combination of hypothermia and CGS-19755. "
05/19/1995 - "Each group had four sets of animals: saline treated controls; hypothermia treated; CGS-19755 treated; and a combination of CGS-19755 + hypothermia treated animals. "
05/19/1995 - "Post-ischemic therapy with CGS-19755 (alone or in combination with hypothermia) in gerbils."
10/01/1993 - "When CGS-19755 was combined with mild hypothermia the effects of repetitive ischemia were completely abolished in all but one gerbil. "
10/01/1993 - "CGS-19755 is neuroprotective during repetitive ischemia: this effect is significantly enhanced when combined with hypothermia."
|4.||Craniocerebral Trauma (Head Injury)
09/01/1999 - "First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (CGS 19755) in patients with severe head injury."
09/15/1995 - "The optimal dose of CGS 19755 (selfotel) for efficacy for severe head trauma has not yet been identified, but may be > 3 mg/kg, as at this dose there was evidence of an ICP lowering effect and improved CPP. "
11/01/1999 - "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. "
09/15/1995 - "Over fifty patients with severe head injury, and one hundred with stroke, have now been treated with the competitive NMDA antagonist CGS 19755 (selfotel). "
09/01/1999 - "A dose escalation, safety, and tolerability study of a competitive antagonist to the N-methyl-D-aspartate (NMDA) glutamate receptor (CGS 19755, Selfotel) in patients with severe head injury is reported. "
|5.||Brain Ischemia (Cerebral Ischemia)
09/01/1995 - "Correlation of CGS 19755 neuroprotection against in vitro excitotoxicity and focal cerebral ischemia."
01/01/1992 - "In vivo distribution of CGS-19755 within brain in a model of focal cerebral ischemia."
07/01/1995 - "In vitro binding of [3H]nimodipine and [3H]CGS-19755 to rat brain in focal cerebral ischemia."
06/01/1990 - "We conclude that CGS-19755 prevents calcium entry into ischemic neurons and may be effective therapy for very acute cerebral ischemia."
07/01/1995 - "Quantitative autoradiography was used to measure regional in vitro binding of the L-type VSCC antagonist [3H]nimodipine and the competitive NMDA receptor antagonist [3H]CGS-19755 to rat brain following 4 h of irreversible focal cerebral ischemia. "
|3.||Dizocilpine Maleate (Dizocilpine)
|5.||3- (2- carboxypiperazin- 4- yl)propyl- 1- phosphonic acid (CPP)
|10.||Excitatory Amino Acids